Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A1DG
|
|||
| Drug Name |
KO-947
|
|||
| Synonyms |
ODIUJYZERXVGEI-UHFFFAOYSA-N; KO947; 1695533-89-1; GTPL9976; SCHEMBL16619993; EX-A1980; BCP25116; HY-112181; CS-0043627; 6-benzyl-3-pyridin-4-yl-2,5-dihydro-1H-pyrazolo[4,3-g]quinazolin-7-one; 6-benzyl-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[4,3-g]quinazolin-7-one; KO947,1695533-89-1,1,5,6,8-Tetrahydro-6-(phenylmethyl)-3-(4-pyridinyl)-7H-pyrazolo[4,3-g]quinazolin-7-one,KO947,KO-947,KO 947
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Kura Oncology San Diego, CA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H17N5O
|
|||
| Canonical SMILES |
C1C2=CC3=C(C=C2NC(=O)N1CC4=CC=CC=C4)NN=C3C5=CC=NC=C5
|
|||
| InChI |
1S/C21H17N5O/c27-21-23-18-11-19-17(20(25-24-19)15-6-8-22-9-7-15)10-16(18)13-26(21)12-14-4-2-1-3-5-14/h1-11H,12-13H2,(H,23,27)(H,24,25)
|
|||
| InChIKey |
ODIUJYZERXVGEI-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ephrin type-B receptor 2 (EPHB2) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Axon guidance | |||
| Panther Pathway | Angiogenesis | |||
| Pathway Interaction Database | EPHB forward signaling | |||
| EphrinB-EPHB pathway | ||||
| Syndecan-2-mediated signaling events | ||||
| Ephrin B reverse signaling | ||||
| Reactome | EPH-Ephrin signaling | |||
| L1CAM interactions | ||||
| EPHB-mediated forward signaling | ||||
| EPH-ephrin mediated repulsion of cells | ||||
| WikiPathways | Transcriptional activation by NRF2 | |||
| NLR Proteins | ||||
| Regulation of Microtubule Cytoskeleton | ||||
| L1CAM interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.